Prof. Rautou

Liver sinusoidal endothelial cell (LSEC) capillarization in NASH

Prof. Pierre-E.Rautou (France) discusses the effects of Liver Sinusoidal endothelial cell (LSEC) capillarization in patients with NASH. He also reviews the occurrences of LSEC capillarization at the early stages of NASH and its contribution to NASH progression by favoring inflammation and liver fibrosis. For the clinicians, he demonstrates a 24 week study of patients with NASH, exposed placebo and lanifibranor treatments strategies to determine LSEC changes.

Read More

The course of liver histology and morbi-mortality in NAFLD / NASH

Prof. Manuel Romero-Gomez discusses the course of liver histology and its impact on mortality and morbidity in patients with NAFLD and NASH. He clarifies how fibrosis determines the prognosis of NAFLD and is the main therapeutic target. The importance of steatosis is also discussed both at the early phase and advanced phase. Finally he reviews the association with HCC and CV risks.

Read More
Prof. Jeffrey V Lazarus

Defining comprehensive models of care for NAFLD Liver health specialists

NAFLD places a substantial burden on healthcare systems and receives little attention from public health authorities. Ambitious measures are needed to improve preparedness globally. Prof Lazarus, Spain, discusses how to establish care pathways tailored to meet patients needs but also that optimally use existing resources. Modifiable risks factors are particularly important in a comprehensive strategy.

Read More
Prof. Bugianesi

HCC in Patients with NAFLD/NASH

Prof Bugianesi, Italy, reviews a burning issue: hepatocellular carcinoma (HCC) in patients with NAFLD/ NASH. She reviews the epidemiology globally and impact on liver transplant. There are multiple risks factors for HCC in NASH patients such as obesity, type 2 diabetes (T2D), and the metabolic syndrome in general. For clinicians, she presents the main studies, the profiles of the patients particularly at risk and risk stratifications strategies.

Read More
Prof. Sanyal

NASH is part of a multi-system disorder

Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease. He makes the point that NASH is part of a multi-system disorder and also presents the key concepts related to management, including risk stratification. An important learning is not to miss opportunities of early identification of patients at risks to improve the patients’ journey.

Read More
Prof. Sven Francque

From number-one liver disease to multi-system disease: NASH, a major unmet clinical need

In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.

Read More
Prof. F. Tacke

Inflammation in NASH and the transition to HCC: an update on scientific breakthroughs by Dr Peiseler and Prof Tacke, Germany

As the International NASH day draws more attention to NASH, it’s important to remember that hepatocarcinoma (HCC) is the 2nd most common cause of cancer related death. Dr M. Peiseler and Dr F. Tacke, Charité hospital, Berlin, Germany present the latest scientific information about NASH as a systemic disease, represented by a common inflammatory ‘NAFLD phenotype’ of myeloid cells in liver and bone marrow. They highlight the role of inflammation and its multiple markers.

Read More